Liersch, Torsten

[["dc.bibliographiccitation.firstpage","1008"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1019"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Raab, Rudolf"],["dc.contributor.author","Hess, Clemens"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Hutter, Matthias"],["dc.contributor.author","Hager, Eva"],["dc.contributor.author","Karstens, Johann"],["dc.contributor.author","Ewald, Hermann"],["dc.contributor.author","Christen, Norbert"],["dc.contributor.author","Jagoditsch, Michael"],["dc.contributor.author","Martus, Peter"],["dc.contributor.author","Sauer, Rolf"],["dc.date.accessioned","2018-11-07T11:04:07Z"],["dc.date.available","2018-11-07T11:04:07Z"],["dc.date.issued","2007"],["dc.description.abstract","Purpose: The impact of the delivery of radiotherapy (RT) on treatment results in rectal cancer patients is unknown. Methods and Materials: The data from 788 patients with rectal cancer treated within the German CAO/AIO/ARO-94 phase III trial were analyzed concerning the impact of the delivery of RT (adequate RT: minimal radiation RT dose delivered, 4300 cGy for neoadjuvant RT or 4700 cGy for adjuvant RT; completion of RT in < 44 days for neoadjuvant RT or < 49 days for adjuvant RT) in different centers on the locoregional recurrence rate (LRR) and disease-free survival (DFS) at 5 years. The LRR, DFS, and delivery of RT were analyzed as endpoints in multivariate analysis. Results: A significant difference was found between the centers and the delivery of RT. The overall delivery of RT was a prognostic factor for the LRR (no RT, 29.6% +/- 7.8%; inadequate RT, 21.2% +/- 5.6%; adequate RT, 6.8% +/- 1.4%; p = 0.0001) and DFS (no RT, 55.1% +/- 9.1%; inadequate RT, 57.4% +/- 6.3%; adequate RT, 69.1% +/- 2.3%; p = 0.02). Postoperatively, delivery of RT was a prognostic factor for LRR on multivariate analysis (together with pathologic stage) but not for DFS (independent parameters, pathologic stage and age). Preoperatively, on multivariate analysis, pathologic stage, but not delivery of RT, was an independent prognostic parameter for LRR and DFS (together with adequate chemotherapy). On multivariate analysis, the treatment center, treatment schedule (neoadjuvant vs. adjuvant RT), and gender were prognostic parameters for adequate RT. Conclusion: Delivery of RT should be regarded as a prognostic factor for LRR in rectal cancer and is influenced by the treatment center, treatment schedule, and patient gender. (c) 2007 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2006.10.020"],["dc.identifier.isi","000245021100008"],["dc.identifier.pmid","17197130"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51762"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","25th Congress of the European-Society-for-Therapeutic-Radiology-and-Oncology"],["dc.relation.eventlocation","Leipzig, GERMANY"],["dc.relation.issn","0360-3016"],["dc.title","Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Sauer, R."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Merkel, S."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Witzigmann, Helmut"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T08:56:08Z"],["dc.date.available","2018-11-07T08:56:08Z"],["dc.date.issued","2011"],["dc.identifier.isi","000208880300290"],["dc.identifier.pmid","28020337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23066"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","8688"],["dc.bibliographiccitation.issue","34"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","8696"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Rodel, C."],["dc.contributor.author","Martus, Peter"],["dc.contributor.author","Papadoupolos, Thomas"],["dc.contributor.author","Fuzesi, Laszlo"],["dc.contributor.author","Klimpfinger, M."],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Raab, Hans-Rudolf"],["dc.contributor.author","Sauer, R."],["dc.contributor.author","Wittekind, Christian"],["dc.date.accessioned","2018-11-07T10:53:54Z"],["dc.date.available","2018-11-07T10:53:54Z"],["dc.date.issued","2005"],["dc.description.abstract","Purpose We assessed the impact of tumor regression grading (TRG) and its value in correlation to established prognostic factors in a cohort of rectal carcinoma patients treated by preoperative chemoradiotherapy (CRT). Patients and Methods TRG was evaluated on surgical specimens of 385 patients treated within the preoperative CRT arm of the CAO/ARC/AlC-94 trial: 50.4 Gy was delivered, fluorouracil was given in the first and fifth week, and surgery was performed 6 weeks thereafter. TRG was determined by the amount of viable tumor versus fibrosis, ranging from TRG 4 when no viable tumor cells were detected, to TRG 0 when fibrosis was completely absent. TRG 3 was defined as regression more than 50% with fibrosis outgrowing the tumor mass, TRG 2 was defined as regression less than 50%, and TRG 1 was defined basically as a morphologically unaltered tumor mass. We performed an initially unplanned, hypothesis-generating analysis with respect to the prognostic value of this TRG system. Results TRG 4, 3, 2, 1, 0 was found in 10.4%, 52.2%, 13.8%, 15.3%, and 8.3% of the resected specimens, respectively. Five-year disease-free survival (DFS) after CRT and curative resection was 86% for TRG 4, 75% for grouped TRG 2 + 3, and 63% for grouped TRG 0 + 1 (P = .006). On multivariate analysis, the pathologic T category and the nodal status after CRT were the most important independent prognostic factors for DFS. Conclusion In this exploratory analysis, complete (TRG 4) and intermediate pathologic response (TRG 2 + 3) suggested improved DFS after preoperative CRT. TRG assessment should be implemented in pathologic evaluation and prospectively validated in further studies."],["dc.identifier.doi","10.1200/JCO.2005.02.1329"],["dc.identifier.isi","000233690200021"],["dc.identifier.pmid","16246976"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49451"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","41st Annual Meeting of the American-Society-of-Clinical-Oncology"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0732-183X"],["dc.title","Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","281"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","290"],["dc.bibliographiccitation.volume","144"],["dc.contributor.author","Kosmala, Rebekka"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Flentje, Michael"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Hofheinz, Ralf-Dieter"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Staib, Ludger"],["dc.contributor.author","Grabenbauer, Gerhard G."],["dc.contributor.author","Folprecht, Gunnar"],["dc.contributor.author","Kirste, Simon"],["dc.contributor.author","Uter, Wolfgang"],["dc.contributor.author","Gall, Christine"],["dc.contributor.author","Rödel, Claus"],["dc.contributor.author","Polat, Bülent"],["dc.date.accessioned","2021-04-14T08:30:31Z"],["dc.date.available","2021-04-14T08:30:31Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.ejca.2020.11.029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83269"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0959-8049"],["dc.title","Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","190"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Hess, C."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Mrak, Karl"],["dc.contributor.author","Merkel, S."],["dc.contributor.author","Raab, H-R"],["dc.contributor.author","Sauer, R."],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T09:38:36Z"],["dc.date.available","2018-11-07T09:38:36Z"],["dc.date.issued","2014"],["dc.format.extent","88"],["dc.identifier.isi","000337052500214"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33099"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","20th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","The prognostic role of tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: 11-year median follow-up results of the CAO/ARO/AIO-94 trial"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","54"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Merkel, Susanne"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Raab, Hans-Rudolf"],["dc.contributor.author","Tschmelitsch, Joerg"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:22:42Z"],["dc.date.available","2018-11-07T09:22:42Z"],["dc.date.issued","2013"],["dc.description.abstract","Introduction: The CAO/ARO/AIO-94 phase-III-trial demonstrated a significant improvement of preoperative chemoradiotherapy (CRT) versus postoperative CRT on local control for UICC stage II/III rectal cancer patients, but no effect on long-term survival. In this add-on evaluation, we investigated the association of gender and age with acute toxicity and outcome. Patients and methods: According to actual treatment analyses, 654 of 799 patients had received pre-(n = 406) or postoperative CRT (n = 248); in 145 patients postoperative CRT was not applied. Gender, age and clinicopathological parameters were correlated with CRT-associated acute toxicity and survival. Results: The 10-year survival was higher in women than in men, with 72.4% versus 65.6% for time to recurrence (p = 0.088) and 62.7% versus 58.4% for overall-survival (OS) (p = 0.066), as expected. For patients receiving CRT, women showed higher hematologic (p < 0.001) and acute organ toxicity (p < 0.001) in the entire cohort as well as in subgroup analyses according to pre- (p = 0.016) and postoperative CRT (p < 0.001). Lowest OS was seen in patients without acute toxicity (p = 0.0271). Multivariate analyses for OS showed that acute organ toxicity (p = 0.034) was beneficial while age (p < 0.001) was associated with worse OS. Discussion: Female gender is significantly associated with CRT-induced acute toxicity in rectal cancer. Acute toxicity during CRT may be associated with improved long-term outcome. (C) 2013 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.radonc.2013.05.009"],["dc.identifier.isi","000324155900007"],["dc.identifier.pmid","23768685"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29411"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0167-8140"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","658"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","664"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Rodel, Claus"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Hess, Clemens"],["dc.contributor.author","Hofheinz, Ralf"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Post, Stephen G."],["dc.contributor.author","Raab, Rudolf"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Wenz, Frederick"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:36:34Z"],["dc.date.available","2018-11-07T08:36:34Z"],["dc.date.issued","2010"],["dc.description.abstract","Background In the era of preoperative chemoradiotherapy (CRT) and total mesorectal excision (TME), the development of distant metastases is the predominant mode of failure in rectal cancer patients today Integrating more effective systemic therapy into combined modality programs is the challenge The question that needs to be addressed is how and when to apply systemic treatment with adequate dose and intensity Material and Methods This review article focuses on phase II-III trials designed to improve 5-fluorouracil (5-FU)-based combined modality treatment for rectal cancer patients through the inclusion of concurrent, adjuvant or, most recently, induction combination chemotherapy Computerized bibliographic searches of PubMed were supplemented with hand searches of reference lists and abstracts of ASC0/ASTR0/ESTR0 meetings Results After preoperative CRT and surgical resection, approximately one third of patients do not receive adjuvant chemotherapy, mainly due to surgical complications, patients' refusal, or investigator's discretion In order to be able to apply chemotherapy with sufficient dose and intensity, an innovative approach is to deliver systemic therapy prior to preoperative CRT rather than adjuvant chemotherapy Emerging evidence from several phase II trials and, recently, randomized phase II trials indicate that induction chemotherapy is feasible, does not compromise CRT or surgical resection, and enables the delivery of chemotherapy in adequate dose and intensity Although this approach did not increase Local efficacy in recent trials (e g pathological complete response rates, tumor regression, R0 resection rates local control), it may help to improve control of distant disease Conclusion Whether this improvement in applicability and dose density of chemotherapy will ultimately translate into improved disease-free survival will have to be tested in a Larger phase III trial"],["dc.identifier.doi","10.1007/s00066-010-2194-2"],["dc.identifier.isi","000285069900002"],["dc.identifier.pmid","21136027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18343"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","Induction Chemotherapy before Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer Is It Time for a Randomized Phase III Tnal?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal of the National Cancer Institute"],["dc.bibliographiccitation.volume","109"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Grabenbauer, Gerhard G"],["dc.contributor.author","Hartmann, Arndt"],["dc.contributor.author","Kaufmann, Marco"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Hoffmanns, Hans"],["dc.contributor.author","Raab, Hans-Rudolf"],["dc.contributor.author","Hothorn, Torsten"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Rödel, Claus"],["dc.date.accessioned","2020-12-10T18:19:20Z"],["dc.date.available","2020-12-10T18:19:20Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/jnci/djx095"],["dc.identifier.eissn","1460-2105"],["dc.identifier.issn","0027-8874"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75211"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","188"],["dc.contributor.author","Sauer, R."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Merkel, S."],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Raab, H-R"],["dc.contributor.author","Villanueva, M.-T"],["dc.contributor.author","Witzigmann, Helmut"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T09:09:23Z"],["dc.date.available","2018-11-07T09:09:23Z"],["dc.date.issued","2012"],["dc.identifier.isi","000309231200072"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26248"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","18th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.title","Preoperative vs. postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","31"],["dc.bibliographiccitation.volume","34 Suppl 3"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hegewisch-Becker, Susanna"],["dc.contributor.author","Höhler, Thomas"],["dc.contributor.author","Knoefel, Wolfram Trudo"],["dc.contributor.author","Kubicka, Stefan"],["dc.contributor.author","Lang, Hauke"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Luster, Markus"],["dc.contributor.author","Oettle, Helmut"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Ridwelski, Karsten"],["dc.contributor.author","Riess, Hanno"],["dc.contributor.author","Rödel, Claus"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Schmiegel, Wolff"],["dc.contributor.author","Schmoll, Hans-Joachim"],["dc.contributor.author","Vanhoefer, Udo"],["dc.date.accessioned","2019-07-09T11:53:49Z"],["dc.date.available","2019-07-09T11:53:49Z"],["dc.date.issued","2011"],["dc.description.abstract","Der XI. Interdisziplinäre Expertenworkshop «Gastrointestinale Tumore», an dem 19 Vertreter der Fachbereiche internistische Onkologie, Gastroenterologie, Strahlentherapie, Chirurgie, Nuklearmedizin und Pathologie teilnahmen, bot einen Überblick über den aktuellen Stand der Wissenschaft im Bereich der gastrointestinalen Karzinome, wobei der Schwerpunkt auf dem Kolon-/Rektum- und Magenkarzinom lag, da in diesen Bereichen die meisten neuen Entwicklungen zu verzeichnen waren. Der Workshop versteht sich als ein interaktives Diskussionsforum zur aktuellen Standortbestimmung von Diagnostik und Therapie sowie zur Thesengenerierung für neue wissenschaftliche und therapeutische Ansätze. Schwerpunkte der diesjährigen Veranstaltung waren zum einen die adjuvante Therapie des Kolonkarzinoms und die First-Line-Therapie des metastasierten kolorektalen Karzinoms, denn in diesen Indikationen haben neue Studiendaten jetzt eine weitere Klärung des Therapiealgorithmus herbeigeführt. Darüber hinaus war die perioperative Therapie bei Lebermetastasen ein wichtiges Thema, zu dem aktuelle Studienkonzepte vorgestellt wurden. Des Weiteren wurde die HER2- Diagnostik beim Magenkarzinom intensiv diskutiert, denn diese unterscheidet sich deutlich von der beim Mammakarzinom. Bei korrekter Diagnostik ist das HER2-positive Magenkarzinom offenbar deutlich weiter verbreitet als bisher angenommen. Viel Beachtung fanden auch die Ergebnisse von 2 aktuellen Phase-III-Studien beim Pankreaskarzinom, die das therapeutische Vorgehen verändern werden und erstmals seit langem einen Fortschritt bei diesem schwer therapierbaren Tumor bedeuten dürften. Die wichtigsten Ergebnisse der 2-tägigen Diskussionsrunde sind im vorliegenden Supplement zusammengefasst."],["dc.identifier.doi","10.1159/000328047"],["dc.identifier.fs","582631"],["dc.identifier.pmid","21577036"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8060"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60502"],["dc.language.iso","de"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1423-0240"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.mesh","Clinical Trials as Topic"],["dc.subject.mesh","Evidence-Based Medicine"],["dc.subject.mesh","Gastrointestinal Neoplasms"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Interdisciplinary Studies"],["dc.subject.mesh","Medical Oncology"],["dc.title","Gastrointestinal tumors-interdisciplinary discussion over new data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]